Back to Search
Start Over
Distinctive grade based on Ki67 index and immune microenvironment of metastatic pancreatic neuroendocrine tumors responding to capecitabine plus temozolomide.
- Source :
-
BMC cancer [BMC Cancer] 2024 Nov 07; Vol. 24 (1), pp. 1362. Date of Electronic Publication: 2024 Nov 07. - Publication Year :
- 2024
-
Abstract
- Background: Ki67 index changes during the treatment of metastatic pancreatic neuroendocrine tumor (PanNET) treatment. The study aimed to detect alterations of grade based on Ki67 index and immune microenvironment in PanNET responding to capecitabine/temozolomide (CapTem).<br />Method: Retrospective data of patients with PanNET were collected. In control group, 35 patients underwent surgery immediately after biopsy. In CapTem group, 38 patients received CapTem after biopsy and responded well to treatment (defined as either stable disease or partial response), and subsequently underwent surgery. All patients have pathological Ki67 index at biopsy and after surgery. CD163 + CD68 + CD206 + M2 macrophages, CD68 + CD86 + CD80 + M1 macrophages, CD11b + CD33 + myeloid-derived suppressor cells, and CD4 + CD25 + regulatory T cells were stained using multiplex immunofluorescence.<br />Results: In control group, the paired grade based on Ki67 index directly after surgery showed no upgrade or downgrade compared to biopsy. In patients who responded well to CapTem, the grade based on Ki67 index before and after CapTem was altered. Thirteen patients had upgraded Ki67 index and 11 patients had downgraded. The proportion of stable disease was higher in the upgraded group compared to downgraded group (p = 0.0155). And upgraded group had a significantly shorter mPFS than patients in the downgrade group (8.5 months vs. 20 months, HR 4.834, 95% CI 1.414 to 16.53, p = 0.012). M1 macrophages was significantly lower in the downgraded group than in the Ki67 upgraded group (p < 0.001).<br />Conclusion: Grade based on Ki67 index and immune environment change in PanNET patients responding well to CapTem. Patients with downgraded had longer mPFS compared to those with upgraded. It is necessary to reassess the Ki67 index after CapTem treatment, even in patients responding well to CapTem.<br /> (© 2024. The Author(s).)
- Subjects :
- Humans
Female
Male
Middle Aged
Retrospective Studies
Aged
Adult
Neoplasm Grading
Treatment Outcome
Temozolomide therapeutic use
Temozolomide pharmacology
Temozolomide administration & dosage
Capecitabine therapeutic use
Capecitabine administration & dosage
Pancreatic Neoplasms drug therapy
Pancreatic Neoplasms immunology
Pancreatic Neoplasms pathology
Ki-67 Antigen metabolism
Tumor Microenvironment immunology
Tumor Microenvironment drug effects
Neuroendocrine Tumors drug therapy
Neuroendocrine Tumors immunology
Neuroendocrine Tumors pathology
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1471-2407
- Volume :
- 24
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- BMC cancer
- Publication Type :
- Academic Journal
- Accession number :
- 39511555
- Full Text :
- https://doi.org/10.1186/s12885-024-13117-5